Breakthrough Real-World Evidence Powering Blood Cancer Research in 2025

City of Hope researchers presented compelling real-world evidence (RWE) at the 2025 ASCO Annual Meeting, highlighting its role in reshaping treatments for various cancers including potential blood cancers through genomic biomarkers and population studies.2

Florida Cancer Specialists & Research Institute (FCS) showcased RWE capabilities at the 2025 SOHO meeting, with over one million patients' data driving advances in understanding blood cancers and accelerating new therapies; FCS Director of Real-World Evidence Amanda Warner presented two abstracts.6

Multiple 2025 ASH Annual Meeting presentations, including from UChicago Medicine, Blood Cancer United, and Rutgers Cancer Institute/RWJBarnabas Health, featured breakthrough blood cancer research, emphasizing technology advances like MRD testing to improve safety, access, and outcomes in leukemias.3 7 8 9

Advances in sensitive MRD detection via NGS and other tests emerged as key predictors for outcomes in acute myeloid leukemia (AML) and other blood cancers, guiding treatment decisions and serving as surrogate endpoints in trials.3

RWE and clinical expertise from large patient cohorts are powering precision oncology and novel therapies in hematologic malignancies at major 2025 conferences.2 6